Open Access

Inhibition of osteoclastogenesis for periprosthetic osteolysis therapy through the suppression of p38 signaling by fraxetin

  • Authors:
    • Jia‑Cheng Liao
    • Zhao‑Xia Wei
    • Chang Zhao
    • Zhong‑Ping Ma
    • Dao‑Zhang Cai
  • View Affiliations

  • Published online on: May 21, 2018     https://doi.org/10.3892/ijmm.2018.3698
  • Pages: 1257-1264
  • Copyright: © Liao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Periprosthetic osteolysis belongs to osteolytic diseases, which often occur due to an imbalance between osteoclast and osteoblast number or activity. Fraxetin, a natural plant extract, inhibits osteoblast apoptosis and has therapeutic potential for treating osteolytic diseases. However, data pertaining to the effects of fraxetin on osteoclasts are limited. In the present study, it was demonstrated that the inhibition of osteoclastogenesis by fraxetin had an important role on the therapy of titanium particle‑induced osteolysis in vivo. In addition, fraxetin was demonstrated to suppress receptor activator of nuclear factor‑κB ligand (RANKL)‑mediated osteoclast differentiation and bone resorption in vitro in a dose‑dependent manner. Fraxetin inhibited osteoclast differentiation and function through the suppression of p38 signaling and subsequently, the suppression of osteoclast‑specific gene expression, including tartrate‑resistant acid phosphatase, nuclear factor of activated T‑cells, cytoplasmic 1, and cathepsin K. In conclusion, fraxetin administration may have potential as a treatment method for periprosthetic osteolysis and other osteolytic diseases.
View Figures
View References

Related Articles

Journal Cover

September-2018
Volume 42 Issue 3

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liao JC, Wei ZX, Zhao C, Ma ZP and Cai DZ: Inhibition of osteoclastogenesis for periprosthetic osteolysis therapy through the suppression of p38 signaling by fraxetin. Int J Mol Med 42: 1257-1264, 2018.
APA
Liao, J., Wei, Z., Zhao, C., Ma, Z., & Cai, D. (2018). Inhibition of osteoclastogenesis for periprosthetic osteolysis therapy through the suppression of p38 signaling by fraxetin. International Journal of Molecular Medicine, 42, 1257-1264. https://doi.org/10.3892/ijmm.2018.3698
MLA
Liao, J., Wei, Z., Zhao, C., Ma, Z., Cai, D."Inhibition of osteoclastogenesis for periprosthetic osteolysis therapy through the suppression of p38 signaling by fraxetin". International Journal of Molecular Medicine 42.3 (2018): 1257-1264.
Chicago
Liao, J., Wei, Z., Zhao, C., Ma, Z., Cai, D."Inhibition of osteoclastogenesis for periprosthetic osteolysis therapy through the suppression of p38 signaling by fraxetin". International Journal of Molecular Medicine 42, no. 3 (2018): 1257-1264. https://doi.org/10.3892/ijmm.2018.3698